Targeted Therapies for the Neurofibromatoses

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Neurofibromatosis tumors often require distinct management strategies compared to spontaneous tumors.
• Current focus is on symptom minimization due to risks of tumor persistence and growth.

Purpose of the Study:

• To review the translation of preclinical data into therapeutic trials for neurofibromatosis.
• To highlight advancements in managing neurofibromatosis type 1 and type 2.

Main Methods:

• Review of preclinical data and therapeutic trial outcomes.
• Focus on targeted therapies for specific neurofibromatosis subtypes.

Main Results:

• MEK inhibition demonstrates success in treating neurofibromatosis type 1 with progressive optic pathway gliomas or plexiform neurofibromas.
• Therapeutic success for malignant NF1 tumors (gliomas, MPNSTs) and for neurofibromatosis type 2 and schwannomatosis remains limited.

Conclusions:

• Targeted therapies, like MEK inhibitors, represent a significant advancement for specific neurofibromatosis type 1 manifestations.
• Further research is crucial for developing effective treatments for malignant NF1 tumors and for neurofibromatosis type 2 and schwannomatosis.